In Vitro Diagnostics

Development Progress

Integrated Diagnostics’ current programs include developing highly-multiplexed, blood-based diagnostics for early detection of lung cancer and Alzheimer’s disease.

The company has in-licensed high quality data sets on organ and disease specific proteins relevant to both indications and has rapidly developed assays capable of monitoring hundreds of these candidate proteins simultaneously. These large-scale assays allow us to cast a wide net for the combinations of biomarkers with the greatest diagnostic value.

Having launched in late 2009, we expect to begin verification studies for both diagnostics in 2011.

Indication Selection: Unmet Need & Available Data

We develop diagnostics for serious indications that affect large numbers of people. We look for conditions with a significant unmet need – ones for which gathering tissue samples is difficult and which are poorly served by genetic tests.

We also look for indications where there are pre-existing, high-quality data sets that we can in-license. That allows us to focus on what we do best: analysis, validation and rapid commercialization.

We invite you to learn more about the company’s strategy here.

Looking Ahead: Multiple Indications & Modalities

The company’s technologies are applicable to a broad range of diseases including diabetes, CNS diseases and cancer.

In addition to early detection, Integrated Diagnostics’ technologies are pertinent to multiple diagnostic modalities including stratification of disease types and monitoring disease progression, treatment and recurrence.